



## DATA SHEET


Antigen	Blood Group A
Clone	BIRMA 1
Product Code	9491
Immunoglobulin Class	Mouse IgM Kappa light chain

**NHS Blood & Transplant**  
500 North Bristol Park  
Northway  
Filton  
Bristol  
BS34 7QH

**Tel:** +44 (0)117 921 7200  
**Fax:** +44 (0)117 912 5796  
**Web:** <http://ibgri.blood.co.uk>

### Antigen Description and Distribution

The histo-blood group A antigen is defined by the carbohydrate structure at the non-reducing termini of oligosaccharide chains of glycoproteins and glycolipids. Carbohydrate chains are synthesized by the action of  $\alpha$ -N-acetyl-D-galactosaminyl-transferase, which catalyzes the transfer of GalNAc monosaccharide to an acceptor substrate called the H antigen. The structure of the A antigen is GalNAc( $\alpha$ 1-3)Gal( $\beta$ 1-3)GlcNAc-R



ABO, of which the A antigen is part of, is the most important blood group system from the clinical blood transfusion perspective. Approximate frequencies of ABO phenotypes in southern England are as follows: O 43%, A 45%, B 8% and AB 4%; but frequencies vary throughout the world. The A antigen is widely distributed on erythrocytes, cells and tissues, and is present, in soluble form, in body fluids of A positive individuals. About 20% of group A people secrete no A substance because their secretions contain no H antigen although they are still blood group A because the H antigen is still present on their erythrocytes. In a rare phenotype, the Bombay phenotype, no H is present in secretions or on the erythrocytes and consequently no A or B are present. The A antigen is divided into 2 main subgroups, A<sub>1</sub> and A<sub>2</sub>.

### Clone

BIRMA 1<sup>1</sup> was made in response to immunisation with salivary glycoprotein from a human blood group A secretor. BIRMA 1 directly agglutinates blood group A erythrocytes. BIRMA-1 accurately grouped all 1,384 adult and 103 cord blood samples initially manually tested. On automated grouping on the Olympus PK7100 no discrepancies were noted with over 64,000 samples tested. The antibody reacts strongly with all the common A subgroups: A<sub>1</sub> titre 1:1024, A<sub>2</sub> titre 1:512, A<sub>1</sub>B titre 1:256 and A<sub>2</sub>B 1:256. Tests using BIRMA-1 with cells bearing rare subgroups of A showed agglutination of A<sub>3</sub>, A<sub>3</sub>B, A<sub>w</sub>B, A Bantu and Oriental: A<sub>2</sub>, A<sub>int</sub>, A<sub>int</sub>B, A<sub>2</sub>B and A<sub>3</sub>B. 11 of the 18 A<sub>x</sub> were agglutinated and there was no reactivity with the 2 B(A) cell samples tested. BIRMA-1 gave no positive reaction with any of the 450 papainized B cells tested. BIRMA-1 gives rapid avidity times: the appearance of agglutination at 3 seconds with A<sub>1</sub>, A<sub>2</sub>, A<sub>1</sub>B and A<sub>2</sub>B and attainment of a 3 + reaction in 16 seconds. The addition of 2% sodium chloride reduced the latter time to 5 seconds.

### Further References/Reading

1. D.F.McDonald and J.M.Thompson (1991) A New Monoclonal Anti-A antibody BIRMA-1. A potent culture supernatant which agglutinates A<sub>x</sub> cells, but does not give undesirable reactions with B cells. *Vox Sang* 61:53-58
2. Achermann F.J. et al. (2005) Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype. *Transfusion and Apheresis Science* 32 255–262.
3. Anstee DJ, Cartron J-P. (1997) Towards an understanding of the red cell surface. In: Garratty G, ed. *Applications of molecular biology to transfusion medicine*:17-49. American Association of Blood Banks, Bethesda, MD.
4. Daniels G. (2013) *Human blood groups* (third Ed.). Blackwell Publishing Ltd.
5. Issitt PD, Anstee DJ (1998) *Applied blood group serology*. 4th edn. Montgomery Scientific Publications, Durham, NC.
6. Mollison PL, Engelfriet CP, Contreras M. (1997) *Blood Transfusion in clinical medicine*. 10th edn. Blackwell Science, Oxford.
7. Reid ME, Lomas-Francis C. and Olsson M. (2012) *The blood group antigen facts book*. Academic Press, London, Third Ed.